There was a meaningful reduction in the risk for non-small cell lung cancer (NSCLC) recurrence or death in post-surgical patients treated with perioperative nivolumab (Opdivo) and chemotherapy ...

Neoadjuvant nivolumab has demonstrated efficacy in patients with mismatch repair-deficient, surgically resectable endometrial cancer.

Use of nivolumab (Opdivo) before chemotherapy was not associated with improved pathologic complete response (pCR) rates among patients with early triple-negative breast cancer (TNBC), but a 12-week ...

A recent study published in JAMA Oncology presents promising new data on a treatment regimen beneficial to patients with a ...

Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of Head and Neck Patients.

CEL-SCI (CVM) announced that a third-party study published on March 6 in JAMA Oncology provided data that support Multikine’s use as a neoadjuvant treatment in patients with tumors having low PD ...

Chemotherapy and immunotherapy followed by de-escalated chemoradiation showed increased survival and reduced side effects in aggressive head and neck cancers that are not associated with human ...

Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines ...

During a live event, Sumanta K. Pal, MD, discusses the efficacy and safety findings from the CheckMate 274 trial of adjuvant ...

Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications ...